Dr. Reddy's Laboratories (DRRD IN) 4QFY22: Double-Digit Sales Growth; One-Off Charge Impacted Profit
Dr. Reddy’s reported strong double-digit revenue growth in Q4, while one-off charges weighed on bottom-line. New product launches in the U.S....
465 Views
Aurobindo Pharma (ARBP IN): Regulatory Issues Continue to Haunt the Company
Aurobindo's U.S. business is under continued pressure and fresh regulatory issue regarding its oral manufacturing facility further delays the...
480 Views
Axis Research Scorecard Report - Mar 2022
Axis Top Picks basket has delivered an astounding return of 127% since its inception, notably beating the 89% return reported by the benchmark...
331 Views
Cipla: Rigor on Portfolio Execution and Cash Generation Initiatives to Support Growth
We initiate coverage on CIPLA Ltd (CIPLA) with a BUY rating and a target price of Rs 1,200 (PE 24x for FY24E EPS), implying an upside of 15.5% from...
371 Views
Dr. Reddy's Laboratories (DRRD IN): India Business Is the Only Bright Spot Amid Many Headwinds
Despite price erosion headwinds in North America generics and revenue exposure to Russia, Dr. Reddy’s Laboratories look attractive due to its...
807 Views